DK1100829T3 - Anvendelse af basiliximab til behandling af rheumatoid arthritis eller hudsygdomme - Google Patents

Anvendelse af basiliximab til behandling af rheumatoid arthritis eller hudsygdomme

Info

Publication number
DK1100829T3
DK1100829T3 DK99944294T DK99944294T DK1100829T3 DK 1100829 T3 DK1100829 T3 DK 1100829T3 DK 99944294 T DK99944294 T DK 99944294T DK 99944294 T DK99944294 T DK 99944294T DK 1100829 T3 DK1100829 T3 DK 1100829T3
Authority
DK
Denmark
Prior art keywords
tyr
treatment
rheumatoid arthritis
skin diseases
phe
Prior art date
Application number
DK99944294T
Other languages
Danish (da)
English (en)
Inventor
Peter Lloyd Amlot
Max H Schreier
Original Assignee
Novartis Ag
Univ London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9816281.1A external-priority patent/GB9816281D0/en
Priority claimed from GBGB9912460.4A external-priority patent/GB9912460D0/en
Application filed by Novartis Ag, Univ London filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1100829T3 publication Critical patent/DK1100829T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK99944294T 1998-07-27 1999-07-26 Anvendelse af basiliximab til behandling af rheumatoid arthritis eller hudsygdomme DK1100829T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9816281.1A GB9816281D0 (en) 1998-07-27 1998-07-27 Organic compounds
GBGB9912460.4A GB9912460D0 (en) 1999-05-27 1999-05-27 Organic compounds
PCT/EP1999/005316 WO2000006604A2 (en) 1998-07-27 1999-07-26 Use of cd25 binding molecules in the treatment of rheumatoid arthritis or skin diseases

Publications (1)

Publication Number Publication Date
DK1100829T3 true DK1100829T3 (da) 2007-12-27

Family

ID=26314120

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99944294T DK1100829T3 (da) 1998-07-27 1999-07-26 Anvendelse af basiliximab til behandling af rheumatoid arthritis eller hudsygdomme

Country Status (11)

Country Link
US (1) US20020110558A1 (pt)
EP (1) EP1100829B1 (pt)
JP (1) JP3973360B2 (pt)
AT (1) ATE372349T1 (pt)
AU (1) AU5728699A (pt)
CY (1) CY1107785T1 (pt)
DE (1) DE69937057T2 (pt)
DK (1) DK1100829T3 (pt)
ES (1) ES2291040T3 (pt)
PT (1) PT1100829E (pt)
WO (1) WO2000006604A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007911D0 (en) * 2000-03-30 2000-05-17 Novartis Ag Organic compounds
ES2314067T3 (es) * 2001-04-06 2009-03-16 University Of Bristol Uso de moleculas de enlace cd 25 en pacientes resistentes a los esteroides.
AU2004275860A1 (en) * 2003-09-23 2005-04-07 Pdl Biopharma, Inc. Treatment of respiratory diseases with anti-IL-2 receptor antibodies
GB0507696D0 (en) * 2005-04-15 2005-05-25 Novartis Ag Organic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU631545B2 (en) * 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules

Also Published As

Publication number Publication date
EP1100829A2 (en) 2001-05-23
WO2000006604A3 (en) 2000-06-15
ATE372349T1 (de) 2007-09-15
AU5728699A (en) 2000-02-21
DE69937057D1 (de) 2007-10-18
EP1100829B1 (en) 2007-09-05
JP3973360B2 (ja) 2007-09-12
JP2002521491A (ja) 2002-07-16
PT1100829E (pt) 2007-12-06
CY1107785T1 (el) 2013-06-19
DE69937057T2 (de) 2008-05-29
ES2291040T3 (es) 2008-02-16
WO2000006604A2 (en) 2000-02-10
US20020110558A1 (en) 2002-08-15

Similar Documents

Publication Publication Date Title
TNSN06087A1 (en) Therapeutic binding molecules
BR0207151A (pt) Moléculas de aglutinação terapêuticas
PE20011219A1 (es) ANTICUERPOS PARA IL-1ß HUMANA
GEP20074222B (en) Antibodies to cd40
AR035581A1 (es) Anticuerpos para il-1beta humana
BR0112086A (pt) Anticorpos para mcp-1 humano
HRP20181069T1 (hr) Antagonistička protutijela na il-17
CO5280086A1 (es) Molecula de enlace de cd154, construccion de adn, vector de expresion, composcion y combinacion farmaceutica
BRPI0511782A (pt) anticorpos anti-cd3 e métodos de uso dos mesmos
NZ594275A (en) B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
ATE472556T1 (de) Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
CU23292B7 (es) Anticuerpos monoclonales humanos de ctla-4
TW200716182A (en) Antibodies directed to CD20 and uses thereof
DK1503794T3 (da) Behandlingsfremgangsmåder ved anvendelse af CTLA-4-antistoffer
NO20061070L (no) Antistoffer mot parathyoidhormon (PTH) og anvendelser derav
DE122012000001I1 (de) Humane antikorper gegen CTLA-4 und deren verwendungen.
WO2003057857A3 (en) Antibodies directed to pdgfd and uses thereof
CY1107785T1 (el) Χρηση του βασιλιξιμαμπ στη θεραπεια της ρευματοειδους αρθριτιδας ´η νοσων του δερματος
BR0109549A (pt) Utilização de moléculas que se ligam a cd25 no tratamento de doenças inflamatórias do trato gastrointestinal
NO20033718D0 (no) Syntetiske humane peptider og farmasöytiske sammensetninger omfattende disse for behandling av systemisk lupus erythematosus
TH53886B (th) แอนติบอดี้ต่อ il-ib ในมนุษย์
TH62172A (th) โมเลกุลยึดประสานที่ใช้บำบัดรักษา
UA93478C2 (ru) Выделенное моноклональное антитело человека, kotopoe связывается c cd20, и его применение
TH64455A (th) สารภูมิต้านทาน mcp-1 ในมนุษย์